Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | TXK | P42681 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919558 | 0.89 | CDC7 (0.40) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2918438 | 0.87 | IGF1R (0.46) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2916270 | 0.87 | CDK4 (0.41) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2920288 | 0.87 | PDGFRB (0.37) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2918594 | 0.85 | CDC7 (0.58) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2912557 | 0.85 | IGF1R (0.45) | PDGFRBPDGFRAIGF1RKDR | |
| SCHEMBL13175217 | 0.84 | PDGFRB (0.36) | CDC7SYKPDGFRBPDGFRAIGF1R | |
| SCHEMBL2917081 | 0.83 | SYK (0.41) | SYKPDGFRBPDGFRALYNTXK | |
| SCHEMBL2917456 | 0.81 | CDK2 (0.35) | CDC7PDGFRBPDGFRAKDM4EALDH1A1 | |
| SCHEMBL2918651 | 0.80 | KIT (0.38) | CDC7SYKBTKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | CDC7 405/4885SYK 724/4885PDGFRB 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.